
कृपया अन्य खोज का प्रयास करें
चिन्ह | एक्सचेंज | करेंसी | ||
---|---|---|---|---|
GMAB | कोपेनहेगेन | DKK | रियल टाइम | |
GMABc | BATS Europe | DKK | देरी | |
GMAB | NASDAQ | USD | रियल टाइम | |
0MGB | लंदन | DKK | रियल टाइम | |
GE91y | ट्रेडगेट | EUR | देरी | |
GMAB | विएना | EUR | रियल टाइम |
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Anders Gersel Pedersen | 73 | 2003 | Non-Independent Director |
Deirdre P. Connelly | 63 | 2017 | Independent Chairman of the Board |
Paolo Paoletti | 73 | 2015 | Independent Director |
Pernille Erenbjerg | 57 | 2015 | Independent Deputy Chairman |
Rolf Karl-Heinz Hoffmann | 65 | 2016 | Independent Director |
Elizabeth G. O'Farrell | 59 | 2022 | Independent Director |
Martin Schultz | 49 | 2022 | Senior Director of Clinical Operations & Non-Independent Director |
Mijke Zachariasse | 51 | 2019 | Senior Director, Head of Antibody Research Materials & Non-Independent Director |
Takahiro Hamatani | 50 | 2022 | Senior Director of Finance Japan & Non-Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है